Inventor · disambiguated record
Gianfranco Caselli
Also filed as: CASELLI GIANFRANCO
27 granted patents·7 pending applications·84 citations·filing 1993–2023
94Inventor score
Top patents by PatentIndex Score
34 records- 0185US9631029B2Anti-ADAMTS-5 antibody, derivatives and uses thereofRottapharm Biotech Srl·Filed 2013·Granted Apr 25, 2017·9 cites·9 claims
- 0279US7994181B26-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agentsROTTAPHARM SPA·Filed 2006·Granted Aug 9, 2011·6 cites·8 claims
- 0378US9365654B2Anti-TrkA antibodies, derivatives and uses thereofRottapharm Biotech Srl·Filed 2013·Granted Jun 14, 2016·2 cites·5 claims
- 0474US6069172A(R)-2-(3-benzoylphenyl) propionic acid salts and pharmaceutical preparations containing themDOMPE SPA·Filed 1999·Granted May 30, 2000·44 cites·24 claims
- 0574US2024091227A1Use Of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline For Treating Neurodegenerative Diseases, Preferably Alzheimer's DiseaseRottapharm Biotech Srl·Filed 2023·Application pending·0 cites
- 0672US11590114B2Pharmaceutical combination of an EP4 antagonist and immune checkpoint inhibitors for the treatment of tumoursRottapharm Biotech Srl·Filed 2020·Granted Feb 28, 2023·1 cites·7 claims
- 0772US7482371B2N-phenylbenzamide derivatives as drugs for the treatment of COPDROTTAPHARM SPA·Filed 2005·Granted Jan 27, 2009·1 cites·3 claims
- 0865US8420634B2Amidine, thiourea and guanidine derivatives of 2-aminobenzothiazoles and aminobenzothiazines for their use as pharmacological agents for the treatment of neurodegenerative pathologiesANZINI MAURIZIO·Filed 2008·Granted Apr 16, 2013·1 cites·5 claims
- 0957US2022257598A1Use of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline for Treating Neurodegenerative Diseases, Preferably Alzheimer's DiseaseRottapharm Biotech Srl·Filed 2020·Application pending·0 cites
- 1056US2008045522A1Omega-aminoalkylamides of r-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cellsDOMPE PHA R MA SPA RES & MFG·Filed 2007·Application pending·0 cites
- 1155US7846921B2Method of relieving symptoms of gastroesophageal reflux diseaseROTTAPHARM SPA·Filed 2006·Granted Dec 7, 2010·0 cites·5 claims
- 1254US9493402B2Omega-aminoalkylamides of R-2-aryl-propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cellsDOMPÉ S P A·Filed 2012·Granted Nov 15, 2016·0 cites·4 claims
- 1353US2010197962A1Use of Neboglamine in the Treatment of ToxicodependencyROTTAPHARM SPA·Filed 2006·Application pending·0 cites
- 1451US12433875B2(R)-4-(1-(6-(4-(trifluoromethyl)benzyl)-6-azaspiro[2.5]octane-5-carboxamido)-cyclopropyl) benzoic acid or its salt also in polymorphic form a for use in the prevention of heterotopic ossificationRottapharm Biotech Srl·Filed 2020·Granted Oct 7, 2025·0 cites·14 claims
- 1551US6881755B2N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing themDOMPE SPA·Filed 2003·Granted Apr 19, 2005·0 cites·1 claims
- 1649US12509446B2FYN and VEGFR2 kinase inhibitorsRottapharm Biotech Srl·Filed 2020·Granted Dec 30, 2025·0 cites·32 claims
- 1748US8633208B26-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligandsGIORDANI ANTONIO·Filed 2008·Granted Jan 21, 2014·0 cites·3 claims
- 1848US8258185B2Use of neboglamine in the treatment of toxicodependencyMAKOVEC FRANCESCO·Filed 2011·Granted Sep 4, 2012·0 cites·10 claims
- 1947US2016244529A1Anti-trka antibodies, derivatives and uses thereofRottapharm Biotech Srl·Filed 2016·Application pending·0 cites
- 2044US8288368B2Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cellsALLEGRETTI MARCELLO·Filed 2002·Granted Oct 16, 2012·0 cites·5 claims
- 2144US5773465ATartronic acids, their acetalic ethers and o-estersDOMPE FARMACEUTICI SPA·Filed 1997·Granted Jun 30, 1998·6 cites·17 claims
- 2243US8372866B22-aryl and 2-heteroaryl 4H-1-benzopyran-4-one-6-amidino derivatives, new pharmacological agents for the treatment of arthritis, cancer and related painROTTAPHARM SPA·Filed 2008·Granted Feb 12, 2013·0 cites·18 claims
- 2343US2011045033A1Combination of Itriglumide and Proton Pump Inhibitors in the Treatment of Gastrointestinal and Related DisordersROTTAPHARM SPA·Filed 2010·Application pending·0 cites
- 2442US8193353B26-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agentsGIORDANI ANTONIO·Filed 2011·Granted Jun 5, 2012·0 cites·12 claims
- 2542US7968558B2Amidine derivatives of 2-heteroaryl-quinazolines and quinolines; potent analgesics and anti-inflammatory agentsROTTAPHARM SPA·Filed 2006·Granted Jun 28, 2011·0 cites·3 claims
- 2642US7906551B23-substituted-1,5-diarly-2-alkyl-pyrroles highly selective and orally effective COX-2 inhibitorsROTTAPHARM SPA·Filed 2006·Granted Mar 15, 2011·0 cites·26 claims
- 2741US2008194877A1Benzamidine Derivatives for Treatment and Prevention of Cancer Therapy Induced MucositisROTTAPHARM SPA·Filed 2006·Application pending·0 cites
- 2840US5908863AGeminal carboxylic acids and esters thereof pharmaceutical formulations containing them useful in the treatment of bone dysmetabolismDOMPE SPA·Filed 1997·Granted Jun 1, 1999·5 cites·7 claims
- 2939US10125121B2FYN kinase inhibitorsRottapharm Biotech Srl·Filed 2015·Granted Nov 13, 2018·0 cites·15 claims
- 3037US6730657B1Recombinant proteins from HGF and MSPDOMPE SPA·Filed 2000·Granted May 4, 2004·0 cites·6 claims
- 3137US5656656ATartronic acids, their acetalic ethers and O-estersDOMPE FARMACEUTICI SPA·Filed 1993·Granted Aug 12, 1997·3 cites·6 claims
- 3236US6551991B1Recombinant proteins derived from HGF and MSPDOMPE SPA·Filed 1999·Granted Apr 22, 2003·3 cites·5 claims
- 3329US6887903B1N-(2-aryl-propionyl)-sulfonamides and pharmaceutical preparations containing themDOMPE SPA·Filed 1999·Granted May 3, 2005·0 cites·12 claims
- 3427US6030949AMacrophage stimulating protein for the treatment of pathologies of the nervous systemDOMPES P A·Filed 1998·Granted Feb 29, 2000·3 cites·4 claims
Join the waitlist — get patent alerts
Get an alert when Gianfranco Caselli files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →